- A dissimilar biosimilar? Lichenoid drug eruption induced by an infliximab biosimilar2018 | Faculty of Medicine in Pilsen
- Binocrit - new biosimilar of epoietin2011 | First Faculty of Medicine
- Biosimilar drugs2017 | First Faculty of Medicine, Third Faculty of Medicine
- The use of biosimilars in hematology2012 | First Faculty of Medicine
- Biosimilar medicines2019 | Publication without faculty affiliation
- What are biosimilars and what do they bring to us?2015 | Third Faculty of Medicine
- Biosimilar drugs: what a rheumatologist should know2023 | First Faculty of Medicine
- Biosimilars: A Multidisciplinary Perspective2016 | First Faculty of Medicine
- Biosimilar teriparatide RGB-102020 | First Faculty of Medicine
- Biosimilar adalimumab in clinical practice2020 | First Faculty of Medicine
- Biosimilar infliximab in a clinical laboratory practice2016 | First Faculty of Medicine
- Biosimilars: controversies as illustrated by rhGH2010 | Second Faculty of Medicine
- Biosimilars in treating inflammatory rheumatic diseases2015 | First Faculty of Medicine
- Biosimilar insulines - new possibilities of diabetes treatment2015 | First Faculty of Medicine
- Biosimilars - therapeutic value, regulation, the role of pharmacists +12019 | Publication without faculty affiliation
- Biosimilar treatment in paediatric gastroenterology - current view2022 | Second Faculty of Medicine
- Benefit of biosimilar monoclonal antibodies in the therapy of inflammatory bowel diseases2022 | First Faculty of Medicine
- Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases2019 | Second Faculty of Medicine
- Biosimilars in the treatment of inflammatory rheumatic diseases2022 | First Faculty of Medicine
- First clinical experience with biosimilar adalimumab FKB327 in patients with inflammatory bowel disease2020 | First Faculty of Medicine
- Biosimilar infliximab in anti-TNF-naïve IBD patients - 1-year clinical follow-up2016 | First Faculty of Medicine
- Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN2019 | Second Faculty of Medicine
- Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab2018 | First Faculty of Medicine
- Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases2020 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications2021 | Faculty of Medicine in Hradec Králové
- Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis2016 | First Faculty of Medicine, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis2016 | First Faculty of Medicine, Second Faculty of Medicine
- Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre2017 | First Faculty of Medicine
- Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre2020 | First Faculty of Medicine